Last reviewed · How we verify
standard intensity warfarin
standard intensity warfarin is a Vitamin K antagonist (VKA) Small molecule drug developed by The First Affiliated Hospital with Nanjing Medical University. It is currently FDA-approved for Atrial fibrillation for stroke prevention, Venous thromboembolism (DVT/PE) treatment and prevention, Mechanical heart valve thromboprophylaxis.
Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) to reduce thrombus formation and prevent blood clots.
Warfarin is a small molecule used as a vitamin K antagonist in standard intensity. It is studied for various conditions, including Antiphospholipid Syndrome, Arterial Thrombosis, and Heart Valve Disease, often in combination with other antithrombotic therapies.
At a glance
| Generic name | standard intensity warfarin |
|---|---|
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Drug class | Vitamin K antagonist (VKA) |
| Target | Vitamin K epoxide reductase complex 1 (VKORC1) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Warfarin acts as a vitamin K antagonist, blocking the enzyme vitamin K epoxide reductase and preventing the carboxylation of clotting factors II, VII, IX, and X in the liver. This reduces the production of functional coagulation factors and prolongs the prothrombin time (PT/INR), thereby decreasing the risk of thromboembolism. Standard intensity warfarin dosing is titrated to maintain an INR of 2–3 for most indications.
Approved indications
- Atrial fibrillation for stroke prevention
- Venous thromboembolism (DVT/PE) treatment and prevention
- Mechanical heart valve thromboprophylaxis
- Acute myocardial infarction with high thromboembolic risk
Common side effects
- Bleeding (major and minor)
- Warfarin-induced skin necrosis
- Gastrointestinal bleeding
- Intracranial hemorrhage
- Drug interactions (food, medications)
Key clinical trials
- Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS
- Trial of Low-intensity Anticoagulation to Reduce GI or Other Bleeding Complications With Equivalent Therapeutic Efficacy in HeartMate 3 LVAD Patients (PHASE4)
- Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial). (PHASE4)
- D-Dimer Determined Anticoagulation INTENSITY in Patients With Mechanical Valve Replacement
- The Efficacy and Safety Study of Dabigatran and Warfarin to Non-valvular Atrial Fibrillation Patients (PHASE4)
- The Effect and Safety of Different Intensity Anticoagulation Therapy in Elderly Patients With Non-valvular Atrial Fibrillation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- standard intensity warfarin CI brief — competitive landscape report
- standard intensity warfarin updates RSS · CI watch RSS
- The First Affiliated Hospital with Nanjing Medical University portfolio CI
Frequently asked questions about standard intensity warfarin
What is standard intensity warfarin?
How does standard intensity warfarin work?
What is standard intensity warfarin used for?
Who makes standard intensity warfarin?
What drug class is standard intensity warfarin in?
What development phase is standard intensity warfarin in?
What are the side effects of standard intensity warfarin?
What does standard intensity warfarin target?
Related
- Drug class: All Vitamin K antagonist (VKA) drugs
- Target: All drugs targeting Vitamin K epoxide reductase complex 1 (VKORC1)
- Manufacturer: The First Affiliated Hospital with Nanjing Medical University — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Atrial fibrillation for stroke prevention
- Indication: Drugs for Venous thromboembolism (DVT/PE) treatment and prevention
- Indication: Drugs for Mechanical heart valve thromboprophylaxis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing